Atjaunināt sīkdatņu piekrišanu

E-grāmata: Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action

  • Formāts: 522 pages
  • Izdošanas datums: 22-Dec-2020
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309669634
Citas grāmatas par šo tēmu:
  • Formāts - EPUB+DRM
  • Cena: 87,65 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: 522 pages
  • Izdošanas datums: 22-Dec-2020
  • Izdevniecība: National Academies Press
  • Valoda: eng
  • ISBN-13: 9780309669634
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

Sickle cell disease (SCD) is a genetic condition that affects approximately 100,000 people in the United States and millions more globally. Individuals with SCD endure the psychological and physiological toll of repetitive pain as well as side effects from the pain treatments they undergo. Some adults with SCD report reluctance to use health care services, unless as a last resort, due to the racism and discrimination they face in the health care system. Additionally, many aspects of SCD are inadequately studied, understood, and addressed.



Addressing Sickle Cell Disease examines the epidemiology, health outcomes, genetic implications, and societal factors associated with SCD and sickle cell trait (SCT). This report explores the current guidelines and best practices for the care of patients with SCD and recommends priorities for programs, policies, and research. It also discusses limitations and opportunities for developing national SCD patient registries and surveillance systems, barriers in the healthcare sector associated with SCD and SCT, and the role of patient advocacy and community engagement groups.

Table of Contents



Front Matter Summary 1 Introduction 2 Societal and Structural Contributors to Disease Impact 3 Screening, Registries, and Surveillance 4 Complications of Sickle Cell Disease and Current Management Approaches 5 Health Care Organization and Use 6 Delivering High-Quality Sickle Cell Disease Care with a Prepared Workforce 7 Developing and Delivering the Next Generation of Therapies 8 Community Engagement and Patient Advocacy 9 Strategic Plan and Blueprint for Sickle Cell Disease Action Appendix A: Public Meeting Agendas and Submissions to the Committee Appendix B: Literature Search Terms and Strategy Appendix C: Committee and Staff Biographies Appendix D: Newborn Screening Results Reporting Protocols for Sickle Cell Disease and Sickle Cell Trait Appendix E: Sickle Cell Data Collection Program Appendix F: Georgia Comprehensive Sickle Cell Center: A Case Study Appendix G: Emory Adult Cystic Fibrosis Program Appendix H: Health Resources and Services Administration Sickle Cell Disease Programs Appendix I: Select Treatments Currently Under Development for Sickle Cell Disease Appendix J: Other Training Models for Hematologists Appendix K: Sickle Cell Community-Based Organizations and Patient Groups in the United States Appendix L: Summary Table of Strategic Plan and Blueprint for Sickle Cell Disease Action Appendix M: Summary Table of Sickle Cell Trait Discussion in Report Appendix N: Glossary
Acronyms and Abbreviations xxi
Summary 1(18)
1 Introduction
19(28)
Scope of Work
20(1)
Study Process and Information Gathering
20(5)
Overview of SCD and SCT
25(8)
The Sickle Cell Patient and the Health Care System
33(1)
Policy Making and Funding for SCD
34(4)
Key SCD Actors
38(2)
Organization of the Report
40(2)
References
42(5)
2 Societal and Structural Contributorsto Disease Impact
47(34)
Introduction
48(1)
Societal Factors
48(6)
Individual Factors
54(6)
Environmental Factors
60(1)
The Burden of SCD
61(11)
Conclusions and Recommendations
72(1)
References
73(8)
3 Screening, Registries, and Surveillance
81(42)
Screening for SCD and SCT
83(8)
Communicating Screening Results
91(5)
The Use of Screening Data
96(3)
Patient Registries
99(4)
Public Health Surveillance
103(2)
Ethical Implications and Privacy Considerations
105(7)
Conclusions and Recommendations
112(1)
References
113(10)
4 Complications of Sickle Cell Disease and Current Management Approaches
123(62)
Introduction
124(1)
Pain in SCD
125(13)
Overview of SCD Complications
138(17)
Management of SCD
155(7)
SCT
162(1)
Conclusions and Recommendations
163(2)
References
165(20)
5 Health Care Organization and Use
185(64)
Introduction
186(1)
Health Care for Children with SCD
186(15)
Transition from Pediatric to Adult Care
201(4)
Health Care for Adults with SCD
205(14)
Comprehensive SCD Care Delivery Model
219(9)
Barriers to Comprehensive Care
228(3)
Services for SCT
231(1)
Conclusions and Recommendations
231(3)
References
234(15)
6 Delivering High-Quality Sickle Cell Disease Care With a Prepared Workforce
249(54)
Guidelines for High-Quality SCD Care
250(9)
Patient-Centered Dimensions of High-Quality Care
259(9)
Promoting Uptake of Recommendations for SCD Care
268(1)
Quality Indicators for SCT and Genetic Counseling for SCD and SCT
269(2)
Summary
271(1)
The Availability of a Trained and Prepared Workforce
272(8)
Training the Next Generation of SCD Care Providers
280(9)
Conclusions and Recommendations
289(4)
References
293(10)
7 Developing and Delivering the Next Generation of Therapies
303(50)
Patient Perspectives
304(3)
Therapies Under Development
307(16)
Clinical Trials and the Drug Approval Process
323(3)
Health Care Delivery Policy
326(4)
Reimbursement Policy
330(6)
Conclusions and Recommendations
336(2)
References
338(15)
8 Community Engagement and Patient Advocacy
353(44)
Historical Perspective
354(3)
Sickle Cell Community-Based Organizations and Patient Advocacy Groups
357(16)
Challenges Faced by Sickle Cell Advocates and Groups
373(3)
Models of Patient Advocacy from Other Rare Diseases
376(9)
Opportunities to Move from Local to System-Level Change
385(2)
Summary
387(4)
Conclusions and Recommendations
391(1)
References
392(5)
9 Strategic Plan and Blueprint for Sickle Cell Disease Action
397(22)
References
417(2)
APPENDIXES
A Public Meeting Agendas and Submissions to the Committee
419(8)
B Literature Search Terms and Strategy
427(6)
C Committee and Staff Biographies
433(8)
D Newborn Screening Results Reporting Protocols for Sickle Cell Disease and Sickle Cell Trait
441(4)
E Sickle Cell Data Collection Program
445(4)
F Georgia Comprehensive Sickle Cell Center: A Case Study
449(2)
G Emory Adult Cystic Fibrosis Program
451(2)
H Health Resources and Services Administration Sickle Cell Disease Programs
453(6)
I Select Treatments Currently Under Development for Sickle Cell Disease
459(10)
J Other Training Models for Hematologists
469(6)
K Sickle Cell Community-Based Organizations and Patient Groups in the United States
475(6)
L Summary Table of Strategic Plan and Blueprint for Sickle Cell Disease Action
481(8)
M Summary Table of Sickle Cell Trait Discussion in Report
489(2)
N Glossary
491